Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
119
datasets available to search
ShareScore release 0.9.0
Dataset results
119 results for “Family Therapy”
Proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy reduces the level of DNA damage in patients with heterozygous familial hypercholesterolemia
<p><span><span>Heterozygous Familial Hypercholesterolaemia (HeFH) is a common autosomal dominant genetic disease (1:300) characterized by elevated LDL-C leading to premature atherosclerosis. Treatment with a PCSK9 inhibitor (iPCSK9) is recommended in high cardiovascular risk FH patients if the treatment goal is not achieved on maximal tolerated statin plus ezetimibe. </span></span><span>The aim of this study was to </span><span><span>examine the changes in DNA damage in HeFH patients associated with iPCSK9 use. </span></span><span>Fifty-seven patients were included: a normolipidemic group (control; n=20) and patients with HeFH (study group; n=36). DNA damage was determined by alkaline comet assay. PCSK9 protein level was assessed by ELISA. </span><span>The levels of Lp(a) in human serum were quantitatively turbidimetrically assay.</span><span> </span><span>PCSK9i treatment was associated with lower DNA damage, Lp(a), PCSK9 and lipid profile than before treatment. However, 20 of 36 patients still had Lp(a) values above 125 nmol/L, and reduced Lp(a) did not correlate with reduced DNA damage. Reduced PCSK9 moderately (r=0.48) correlates with reduced DNA damage</span><span><span>. PCSK9i therapy reduces the level of DNA damage in HeFH patients, regardless of the type of inhibitor. The reduction in DNA damage is not related to the changes in lipid profile or Lp(a) induced by PCSK9i, but it is dependent on PCSK9 level.</span></span></p>
Efficacy and Safety of Gemcabene in Patients With Homozygous Familial Hypercholesterolemia on Stable, Lipid-Lowering Therapy (COBALT-1)
ClinicalTrials.gov study NCT02722408. IPD Sharing: Not stated. Countries: 3. Publications: 1.
Study of Alirocumab (REGN727/SAR236553) in Patients With heFH (Heterozygous Familial Hypercholesterolemia) Who Are Not Adequately Controlled With Their LMT (Lipid-Modifying Therapy)
ClinicalTrials.gov study NCT01709500. IPD Sharing: Not stated. Countries: 4. Publications: 7.
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia (ODYSSEY HIGH FH)
ClinicalTrials.gov study NCT01617655. IPD Sharing: Not stated. Countries: 5. Publications: 7.
Brief Strategic Family Therapy for Adolescent Drug Abusers
ClinicalTrials.gov study NCT00095303. IPD Sharing: Not stated. Countries: 2. Publications: 8.
Study of Alirocumab (REGN727/SAR236553) in Patients With Heterozygous Familial Hypercholesterolemia (HeFH) Undergoing Low-density Lipoprotein (LDL) Apheresis Therapy
ClinicalTrials.gov study NCT02326220. IPD Sharing: Not stated. Countries: 2. Publications: 2.
Family-Focused Therapy for Individuals at High Clinical Risk for Psychosis: A Confirmatory Efficacy Trial
ClinicalTrials.gov study NCT04338152. IPD Sharing: YES. Countries: 2. Publications: 8.
A Pilot Randomized Trial of Video-based Family Therapy for Depressed Home Visited Mothers
ClinicalTrials.gov study NCT04741776. IPD Sharing: Not stated. Countries: 1. Publications: 3.
Culturally Modified Family Based Therapy for Haitian Youth in South Florida
ClinicalTrials.gov study NCT03876171. IPD Sharing: NO. Countries: 1. Publications: 2.
Efficacy and Safety Evaluation of Alirocumab in Patients With Heterozygous Familial Hypercholesterolemia or High Cardiovascular Risk Patients With Hypercholesterolemia on Lipid Modifying Therapy (ODYS
ClinicalTrials.gov study NCT02107898. IPD Sharing: Not stated. Countries: 1. Publications: 2.
CYP19A1 (Cytochrome P450 Family 19 Subfamily A Member 1) Gene and Pharmacogenetics of Response to Testosterone Therapy
ClinicalTrials.gov study NCT01378299. IPD Sharing: YES. Countries: 1. Publications: 2.
Attachment Based Family Therapy for Suicidal Adolescents
ClinicalTrials.gov study NCT01537419. IPD Sharing: Not stated. Countries: 1. Publications: 13.
Efficacy and Safety of Alirocumab (SAR236553/REGN727) Versus Placebo on Top of Lipid-Modifying Therapy in Patients With Heterozygous Familial Hypercholesterolemia Not Adequately Controlled With Their
ClinicalTrials.gov study NCT01623115. IPD Sharing: Not stated. Countries: 14. Publications: 7.
Guided Eight-week Online Acceptance and Commitment Therapy for Distressed Family Caregivers of People With Dementia
ClinicalTrials.gov study NCT04847986. IPD Sharing: NO. Countries: 1. Publications: 1.
Emotion Focused Family Therapy for Parents of Children With Mental Health Difficulties
ClinicalTrials.gov study NCT05603000. IPD Sharing: NO. Countries: 1. Publications: 18.
Investigation of Multi-Family Therapy for Anorexia Nervosa
ClinicalTrials.gov study NCT06203418. IPD Sharing: NO. Countries: 1. Publications: 0.
Comparing the Effectiveness of Two Family-based Therapies in Treating Young Children With Obsessive-Compulsive Disorder
ClinicalTrials.gov study NCT00533806. IPD Sharing: Not stated. Countries: 1. Publications: 1.
Triclosan as Adjunctive Therapy in the Plaque Control in Children From Generalized Aggressive Periodontitis Families.
ClinicalTrials.gov study NCT03642353. IPD Sharing: Not stated. Countries: 1. Publications: 1.
NGGT006 Gene Therapy for Homozygous Familial Hypercholesterolemia
ClinicalTrials.gov study NCT06125847. IPD Sharing: NO. Countries: 1. Publications: 0.
Measurement Training and Feedback System: Family Therapy and CBT
ClinicalTrials.gov study NCT03722654. IPD Sharing: Not stated. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.